Cancer Genetics, Inc. is an emerging leader in DNA-based cancer diagnostics and services some of the most prestigious medical institutions in the world. Our tests target cancers that are difficult to diagnose and predict treatment outcomes. These cancers include hematological, urogenital and HPV-associated cancers. We also offer a comprehensive range of non-proprietary oncology-focused tests and laboratory services that provide critical genomic information to healthcare professionals as well as biopharma and biotech. We have established strong research collaborations with major cancer centers such as Memorial Sloan-Kettering, The Cleveland Clinic, Mayo Clinic and the National Cancer Institute. For further information, please see www.cancergenetics.com.
Latest Results: Q4 2015 Quarterly
- Mar 14 2016 7:30 AM EDT Cancer Genetics, Inc. to Present at 28th Annual ROTH Conference on March 16, 2016
- Mar 10 2016 3:53 PM EST Cancer Genetics, Inc. Announces Strong Fourth Quarter and Full-Year 2015 Results and Provides 2016 Business Update
- Mar 7 2016 9:37 AM EST Cancer Genetics, Inc. Launches Next Generation Sequencing Panel for Diagnosis & Treatment Selection in Solid Tumors, CGI FOCUS::Oncomine™
Cancer Genetics, Inc.
201 Route 17 North
Rutherford, NJ 07070
Life Science Advisors LLC